MRK vs ABT
By Alex · Tickerpine
Merck & Co., Inc. vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | ABT |
|---|---|---|
| Price | $128.66 | $94.12 |
| Market cap | $317.77B | $163.94B |
| P/E ratio | 36.2 | 26.4 |
| ROE | 18.94% | 12.33% |
| Profit margin | 13.59% | 13.90% |
| Revenue growth | 4.90% | 7.80% |
| Dividend yield | 2.64% | 2.68% |
| Beta | 0.22 | 0.62 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs ABT in plain English
- MRK is the bigger company — about 1.9× the market cap of ABT.
- ABT is cheaper on earnings (P/E 26.4 vs 36.2).
- MRK earns a higher return on equity (19% vs 12%).
- ABT is growing revenue faster (8% vs 5%).
- ABT has the higher dividend yield (2.68% vs 2.64%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.